Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,201 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline (placebo) Clear all

Conditions: Prostate Cancer, Erectile Dysfunction
Interventions: Placebo, Erythropoietin (EPO); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Candidiasis
Interventions: Caspofungin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Schizophrenia, Autism Spectrum Disorder
Interventions: Oxytocin, Placebo Comparator; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cytomegalovirus (CMV) Infections
Interventions: V160, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 54
States / cities: Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more

Conditions: Pediatric Anesthesia
Interventions: Dexmedetomidine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 36 Months
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy, Frontotemporal Dementia
Interventions: AL001, Placebo; Biological · Other
Lead sponsor: Alector Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more

Conditions: Healthy
Interventions: meropenem-vaborbactam, Placebo, Moxifloxacin; Drug
Lead sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Covid-19
Interventions: Octagam 10%, Saline Solution; Biological · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Sheffield, Alabama • Loma Linda, California • Newport Beach, California + 11 more

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Enzalutamide, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more

Conditions: Alopecia Areata
Interventions: Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml, Intralesional Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Acute Ischemic Stroke (AIS)
Interventions: Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels); Drug
Lead sponsor: Silver Creek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 22
States / cities: Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more

Conditions: Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 97
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more

Conditions: Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous
Interventions: Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline; Biological · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Insulin
Interventions: Insulin, Regular, Human, Placebo; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 45 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Malignant Melanoma Stage IV
Interventions: DC Vaccine & Cyclophosphamide, DC Vaccine & Placebo; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Scar Prevention, Scar Reduction
Interventions: AZX100 Drug Product, Placebo; Drug
Lead sponsor: Capstone Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Austin, Texas

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more

Conditions: Postoperative Hemorrhage
Interventions: Antithrombin (Recombinant), Placebo; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 4 Days to 30 Days
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pain, Postoperative, Anterior Cruciate Ligament Injuries, Analgesics, Opioid
Interventions: IPACK, PLACEBO; Drug
Lead sponsor: Loyola University; Other
Eligibility: 16 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Asthma
Interventions: Reslizumab, Saline; Biological · Other
Lead sponsor: Ception Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more

Conditions: Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions: benralizumab, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuropathic Pain
Interventions: oxytocin 100 micrograms, Normal Saline (preservative free); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Infections
Interventions: E-101 Solution 300 GU/ml, Saline solution; Drug
Lead sponsor: Excited States, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 34
States / cities: Mobile, Alabama • Los Angeles, California • Stanford, California + 29 more

Conditions: Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee

Search by objective public record fields.

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

Dyad Oxytocin Study (DOS)

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Intralesional Steroids in the Treatment of Alopecia Areata

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

IPACK on Early Pain Scores After ACL Reconstruction

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain

Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients